References
- Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):1–7.
- Drozdz M, Weigert A, Silva F, et al. Achievement of renal anemia KDIGO targets by two different clinical strategies-a european hemodialysis multicenter analysis. BMC Nephrol. 2019;20(1):5.
- Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017;18(1):345.
- Gupta N, Wish JB. Hypoxia-Inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017;69(6):815–826.
- Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing Long-Term dialysis. N Engl J Med. 2019;381(11):1011–1022.
- Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381(11):1001–1010.
- Rhee CM. The interaction between thyroid and kidney disease: an overview of the evidence. Curr Opin Endocrinol Diabetes Obes. 2016;23(5):407–415.
- Naseem F, Mannan A, Dhrolia MF, et al. Prevalence of subclinical hypothyroid- dism in patients with chronic kidney disease on maintenance hemodialysis. Saudi J Kidney Dis Transpl. 2018;29(4):846–851.
- Rhee CM, Kim S, Gillen DL, et al. Association of thyroid functional disease with mortality in a national cohort of incident hemodialysis patients. J Clin Endocrinol Metab. 2015;100(4):1386–1395.
- Xu H, Brusselaers N, Lindholm B, et al. Thyroid function test derangements and mortality in dialysis patients: a systematic review and meta-analysis. Am J Kidney Dis. 2016;68(6):923–932.
- Rhee CM, Chen Y, You AS, et al. Thyroid status, quality of life, and mental health in patients on hemodialysis. Clin J Am Soc Nephrol. 2017;12(8):1274–1283.
- Kalantar SS, You AS, Norris KC, et al. The impact of race and ethnicity upon Health-Related quality of life and mortality in dialysis patients. Kidney Med. 2019;1(5):253–262.
- Tokuyama A, Kadoya H, Obata A, et al. Roxadustat and thyroid-stimulating hormone suppression. Clin Kidney J. 2021;14(5):1472–1474.
- Ichii M, Mori K, Miyaoka D, et al. Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis. BMC Nephrol. 2021;22(1):104.
- Yao B, Wei Y, Zhang S, et al. Revealing a Mutant-Induced receptor allosteric mechanism for the thyroid hormone resistance. iScience. 2019;20:489–496.
- Maxwell PH. A new approach to treating renal anaemia. Nat Rev Nephrol. 2019;15(12):731–732.
- Mima A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: advantages and disadvantages. Eur J Pharmacol. 2021;912:174583.
- Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40–50.
- Mima A, Horii Y. Treatment of renal anemia in patients with hemodialysis using hypoxia-inducible factor (HIF) stabilizer, roxadustat: a short-term clinical study. In Vivo. 2022;36(4):1785–1789.
- Pakfetrat M, Dabbaghmanesh MH, Karimi Z, et al. Prevalence of hypothyroid -dism and thyroid nodule in chronic hemodialysis iranian patients. Hemodial Int. 2017;21(1):84–89.
- Sanai T, Okamura K, Rikitake S, et al. The high prevalence of reversible subclinical hypothyroidism with elevated serum thyroglobulin levels in chronic kidney disease patients. CN. 2017;87(05):237–244.
- Narasaki Y, Sohn P, Rhee CM. The interplay between thyroid dysfunction and kidney disease. Semin Nephrol. 2021;41(2):133–143.
- Pan B, Du X, Zhang H, et al. Relationships of chronic kidney disease and thyroid dysfunction in Non-Dialysis patients: a pilot study. Kidney Blood Press Res. 2019;44(2):170–178.
- Nazzal ZA, Khazneh EN, Rabi RA, et al. Prevalence of hypothyroidism among dialysis patients in palestine: a Cross-Sectional study. Int J Nephrol. 2020;2020:2683123.
- Jain D, Aggarwal HK, Pavan Kumar YM, et al. Evaluation of thyroid dysfunc-tion in patients with nephrotic syndrome. Med Pharm Rep. 2019;92(2):139–144.
- Varghese T, Rejish Kumar VJ, Anand G, et al. Dietary GABA enhances hypoxia tolerance of a bottom-dwelling carp, cirrhinus mrigala by modulating HIF-1α, thyroid hormones and metabolic responses. Fish Physiol Biochem. 2020;46(1):199–212.